Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMVUEZI)

Drug Name
PMID20684608C35 Drug Info
Synonyms GTPL8209; BDBM50324574
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
46864283
TTD Drug ID
DMVUEZI

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Approved Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Rho-associated protein kinase 2 (ROCK2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
KD025 DM548TK Psoriasis vulgaris EA90 Phase 2 [2]
INS-117548 DMA46DO Glaucoma/ocular hypertension 9C61 Phase 1 [3]
GSK269962A DM5I2HL Inflammation 1A00-CA43.1 Clinical trial [4]
PMID28048944-Compound-19 DMPT3V9 N. A. N. A. Patented [5]
PMID28048944-Compound-3 DM1BN74 N. A. N. A. Patented [5]
PMID28048944-Compound-7 DMXZ368 N. A. N. A. Patented [5]
PMID28048944-Compound-4 DMJAUWG N. A. N. A. Patented [5]
PMID28048944-Compound-5 DMAB987 N. A. N. A. Patented [5]
PMID28048944-Compound-6 DM5RCBV N. A. N. A. Patented [5]
PMID28048944-Compound-2 DM9ZXOP N. A. N. A. Patented [5]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Rho-associated protein kinase 1 (ROCK1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Netarsudil DM0LPI9 Open-angle glaucoma 9C61 Approved [6]
SAR-407899 DMF95KD Diabetic nephropathy GB61.Z Phase 2 [7]
H-1152 DM8XH3S Pulmonary arterial hypertension BB01.0 Phase 2 [8]
INS-117548 DMA46DO Glaucoma/ocular hypertension 9C61 Phase 1 [3]
GSK269962A DM5I2HL Inflammation 1A00-CA43.1 Clinical trial [4]
PMID28048944-Compound-19 DMPT3V9 N. A. N. A. Patented [5]
PMID28048944-Compound-3 DM1BN74 N. A. N. A. Patented [5]
PMID28048944-Compound-7 DMXZ368 N. A. N. A. Patented [5]
PMID28048944-Compound-4 DMJAUWG N. A. N. A. Patented [5]
PMID28048944-Compound-5 DMAB987 N. A. N. A. Patented [5]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Large tumor suppressor homolog 2 (LATS2) TTML7FG LATS2_HUMAN Inhibitor [1]
NDR1 protein kinase (STK38) TT27XFN STK38_HUMAN Inhibitor [1]
Rho-associated protein kinase 1 (ROCK1) TTZN7RP ROCK1_HUMAN Inhibitor [1]
Rho-associated protein kinase 2 (ROCK2) TTGWKQJ ROCK2_HUMAN Inhibitor [1]

References

1 Tetrahydroisoquinoline derivatives as highly selective and potent Rho kinase inhibitors. J Med Chem. 2010 Aug 12;53(15):5727-37.
2 Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism. Proc Natl Acad Sci U S A. 2014 Nov 25;111(47):16814-9.
3 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
4 Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities. J Pharmacol Exp Ther. 2007 Jan;320(1):89-98.
5 Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515.
6 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
7 The Rho kinase inhibitor SAR407899 potently inhibits endothelin-1-induced constriction of renal resistance arteries. J Hypertens. 2012 May;30(5):980-9.
8 Emerging treatments for pulmonary arterial hypertension. Expert Opin Emerg Drugs. 2006 Nov;11(4):609-19.